newsfilter
← Latest News
GlobeNewswire·

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through